Ban Uplifted: Pantanjali Products Back In Market

The authorities modified the earlier decision and issued a new one on Saturday, allowing the business to continue producing these pharmaceuticals.

Five items manufactured by Ramdev’s Patanjali are no longer prohibited as a result of an amendment to the order by Uttarakhand.

The Uttarakhand Ayurveda and Unani Licensing Authority has overturned a directive ordering the manufacturing of five drugs for diabetes, blood pressure, goitre, glaucoma, and high cholesterol to cease at Yoga guru Ramdev’s Divya Pharmacy.

The authorities on Saturday amended the former ruling and issued a new one enabling the company to continue producing these medications.

The preceding directive on November 9 contained an error, according to the drug controller of the state health authority GCN Jangpangi, who said it had been issued in a haste. Mr. Jangpangi said, “We should have given the corporation the opportunity to clarify its stance” before imposing the injunction.

Acharya Balkrishna, a trusted assistant of Ramdev, expressed his appreciation to the state administration for correcting the mistake. Five of Divya Pharmacy’s products, Bpgrit, Madhugrit, Thyrogrit, Lipidom tablets, and Eyegrit Gold tablets, were being marketed as treatments for high blood pressure, diabetes, goitre, glaucoma, and high cholesterol when the Authority issued its earlier order directing Divya Pharmacy to halt production of those products.

According to the previous order, the company may only start making these products again after receiving approval for their amended formulation sheets from the relevant authorities.

The action was taken as a result of a complaint made by a doctor from Kerala by the name of KV Babu, who claimed that Divya Pharmacy had broken the Drugs and Magic Remedies (objectionable advertising) Act and the Drugs and Cosmetic Act.

In July, Babu filed a complaint with the Authority about the company, and on October 11, he sent the Authority a second complaint through email.